Effects of Oral Levosimendan on Ambulatory Electrocardiographic Variables

Phase 2

Completed

• Conditions: Transient Ischemic Attack; Stroke
• Interventions: Drug: Placebo; Drug: Levosimendan

• Registration Number: NCT00698763
• Lead Sponsor: Orion Corporation, Orion Pharma

Brief Summary

The primary objective is to explore the safety of low doses of oral levosimendan in patients with recent history of an ischaemic cerebrovascular event (stroke or TIA). The main focus will be on the evaluation of proarrhythmic potential of the different dose regimens.

Detailed Description

This is a prospective, multicentre, phase II, randomized, double-blind, placebo-controlled 2-arm parallel group study with 5 escalating dose-levels of oral levosimendan, each given for 13-18 days. The study population will be randomly allocated either to the levosimendan group or to the placebo group. The double-blind phase with either placebo or levosimendan is preceded by a 13-day long single-blind treatment with placebo (placebo run-in). The study consists of 9 visits (screening visit, 7 visits during the treatment period and an end-of-study visit). Each subject will be on study treatment (including placebo run-in) for 78-108 days and the duration of the study for each subject, including the screening and the end of study visit, is approximately 17 weeks.

Study Timeline

• Study First Submitted: 2008-06-12
• Study First Submitted QC: 2008-06-16
• Study First Posted: 2008-06-17
• Study Start: 2008-08
• Primary Completion: 2009-04
• Study Completion: 2009-09
• Status Verified: 2009-11
• Last Update Submitted: 2009-11-23
• Last Update Posted: 2009-11-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 32

Inclusion Criteria

• Male and female patients 50 to 80 years of age with ischaemic stroke or TIA within 1 to 9 months before the screening visit.

Read More

Exclusion Criteria

• Stroke or TIA due to cardiac embolism, vasculitis or arterial dissection
• Severe hemiparesis or dysphasia, haemodynamically significant uncorrected valve disease or hypertrophic cardiomyopathy or restrictive cardiomyopathy, any acute coronary event or angioplasty or any other major surgery within 1 month, any major surgery during the planned study period
• History of life-threatening ventricular arrhythmia within 3 months.
• History of Torsades de Pointes (TdP) or family history of long QT-syndrome
• Heart rate (HR) < 50 or > 100 bpm.
• Systolic blood pressure (SBP) < 100 mmHg or > 180 mmHg, or diastolic blood pressure (DBP) > 100 mmHg.
• Ventricular tachycardia.
• Episode of atrial fibrillation or atrial flutter lasting > 60 seconds.
• Second or third degree atrioventricular (AV) block.
• Potassium (K) < 3.7 mmol/l or > 5.5 mmol/l.
• Creatinine > 170 µmol/l or on dialysis.
• Blood haemoglobin <10 g/dl; clinically significant hepatic impairment.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
B	Placebo	Placebo
A	Levosimendan	Levosimendan

Primary Outcome Measures

Name	Time	Method
24-h Holter reporting	every 2 weeks

Trial Locations

Locations (7)

Helsinki University Hospital (HUCH); 🇫🇮 Helsinki, Finland

Turku University Hospital (TYKS); 🇫🇮 Turku, Finland

Heidelberg University Clinic; 🇩🇪 Heidelberg, Germany

Debrecen University; 🇭🇺 Debrecen, Hungary

Umeå University Hospital, Strokecenter NVS; 🇸🇪 Umeå, Sweden

Sahlgrenska University Hospital, Dept of Neurology; 🇸🇪 Gothenburg, Sweden

University Hospital, Neurologmottagningen; 🇸🇪 Linköping, Sweden